CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
PSMA ADCdrug
Likely dose
PSMA ADC 2.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01856933
NCT01856933Phase 2Completed
CompareCT.gov

BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study

Heinrich Elinzano, MD·interventional·Posted May 20, 2013·Updated Nov 23, 2021

In Brief

A Phase 2 clinical trial evaluating PSMA ADC for GBM and 2 related conditions. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain tumors. This study will also study how your body metabolizes (breaks down) PSMA ADC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGBM, Glioblastoma Multiforme, Gliosarcoma
CountriesUnited States
CollaboratorsProgenics Pharmaceuticals, Inc., Rhode Island Hospital, University of Texas

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2013
Enrollment StartMay 1, 2013
Primary CompletionNov 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.1 years ago

Interventions

PSMA ADCdrug

2.5 mg/kg, IV, over 60 minutes every 3 weeks